On Wednesday, Pfizer Inc (NYSE:PFE) and BioNTech spoke about progress in developing a potential vaccine for COVID-19. According to the report, the vaccine has showcased significant potential in line with handling the deadly disease.
The deadly COVID-19 pandemic struck the world with an impact causing most of the businesses to incur significant losses. There has been a growing need to contain the situation by development of some top-notch vaccines to help keep the virus in check.
The product by the two businesses has been ranked 17th position among those being tested on humans. It is a global race where different companies are working to develop what works the best. It is a deadly pandemic that has so far infected over 10.5 million persons. In terms of the deaths witnessed, over half a million people have lost their lives.
BioNTech has opened up about its BNT162b1 drug, which was given out in dosages to some 24 persons that volunteered. According to the business giant, the volunteers were checked after about 28 days. It was discovered that they had developed some higher levels of antibodies of the disease.
The value of the vaccine
The administration of the vaccine was through injections. Pfizer said that it was busy looking into the development of some larger trials. The aim will be to showcase the strength of the vaccine in line with yielding outstanding immune activity. This company looks forward to the development of a vaccine with the capacity to cure a real infection.
So far, no single vaccine has been passed for commercial use in the fight against COVID-19.
It is a good thing that the businesses are now looking into four experimental vaccines. All of them are being administered in doses to discover the one that works the best way. The one with the biggest promise will move to the next stage. The two say that the next series of tests will be conducted starting early this month. The vaccine is set to be administered to about 30,000.